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Fractional occupancyAbstract The study of the magnitude and variation of drug response is defined as pharmacody-
namics (PDs). PD models examine plasma concentration and effect relationship. It can predict
the archetypal effect (E) of a drug as a function of the drug concentration (C) and estimate an
unknown PD parameter (hpd). The PD models have been described as fixed, linear, log-linear,
Emax, sigmoid Emax, and indirect PD response. Ligand binding model is an example of a PD model
that works on the underpinning PD principle of a drug, eliciting its pharmacological effect at the
receptor site. The pharmacological effect is produced by the drug binding to the receptor to either
activate or antagonise the receptor. Ligand binding models describe a system of interacting compo-
nents, i.e. the interaction of one or more ligands with one or more binding sites. The Emax model is
the central method that provides an empirical justification for the concentration/dose-effect rela-
tionship. However, for ligand binding models justification is provided by theory of receptor occu-
pancy. In essence, for ligand binding models, the term fractional occupancy is best used to describe
the fraction of receptors occupied at a particular ligand concentration. It is stated that the
fractional occupancy ¼ occupied binding sites=total binding sites, which means the effect of a drug
should depend on the fraction of receptors that are occupied. In the future, network-based systems
pharmacology models using ligand binding principles could be an effective way of understanding
drug-related adverse effects. This will facilitate and strengthen the development of rational drug
therapy in clinical practice.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1.1. Pharmacodynamics
The study of the magnitude and variation of drug response is
defined as pharmacodynamics (PDs). To be explicit, it is the
study of the drug which reaches the systemic circulation after
the onset of administration, its intensity, and duration of
action or response or effect, which are related to the drug con-
centration at its receptor site of action (Rosenbaum, 2011).
The relationship between concentration and effect is usually
non-linear, i.e. double the concentration does not result in a
twofold increase in effect but, it will increase the duration of
effect by one half-life. PD encompasses use of quantitative
tools to measure affinity and efficacy of drugs. Clinical phar-
macology can be divided into pharmacokinetics (PK), PDs
and its integration as pharmacokinetic-pharmacodynamic
(PKPD) models combine the time course of drug concentra-
tion with binding of drug to the target site(s) and subsequent
drug effects. The PKPD relationship is presented in Fig. 1.
PKPD models are therefore useful to describe, understand,
and predict the extent and time course of drug effects. It fol-
lows that the greater the endeavour to incorporate mechanistic
behaviour into the PKPD model the greater its ability to pre-
dict new situations.1.2. Receptors, ligands, binding
Receptors can be defined simply as specific macromolecules at
which a ligand binds and alters the biochemical activity (note
that a ligand may do this by inhibiting the effects of
endogenous substances from stimulating the receptor). Any
macromolecular tissue site where a drug may bind can be
considered a binding site and if this site has some functional
activity then it is a receptor. Drug response is a result of
chemical interactions between a drug and a binding site. The
classification of drug receptors is based on tissue location,
specificity of the drug, and the primary amino acid sequence.
Majority (95%) of the total receptors are protein in nature.
Not all proteins in the plasma membrane are receptors, some
serves as transporters, enzymes or ion channels.
A drug can interact with four principle protein targets such
as ion channels (nimodipine and voltage-gated Ca2+ ion chan-
nels), enzymes (neostigmine and acetylcholinesterase), mem-
brane carriers (tricyclic antidepressants and catecholamine
uptake-1) and receptors (Lambert, 2004). A drug binds and
activates a receptor causing an alteration to a number of intra-
cellular messengers/proteins (effectors). Generally, drugs are
considered to bind to receptors and any chemicals that bind
to receptors are usually termed ligands (e.g. drugs). A ligand
is usually considered to be smaller in size than the receptor;
PHARMACOKINETICS (PK)
Dose Concentraon vs. Time
PHARMACODYNAMICS (PD)
Eﬀect vs. Concentraon 
PK-PD
Dose Eﬀect vs. Time
Figure 1 The pharmacokinetic and pharmacodynamic (PKPD) relationship.
Ligand-binding models and applications 167however, anything that binds with specificity can be considered
a ligand. The chemical structure/moiety of both drugs and
receptors are quite important, even though a small change
can result in diminished or null response. A ligand can bind
either reversibly or irreversibly to a receptor. The action is pro-
duced by interacting the drug binding to the receptor to either
activate or antagonise the receptor. A drug-receptor interaction
can open or close an ion channel across the cell membrane.
The drug concentration at the site of the receptor determi-
nes the intensity of a drug’s effect; however, the drug response
could be influenced by receptor density on the cell surface, sig-
nal transmission mechanism into the cell by second messengers
(substances within the cell), or regulatory factors that control
gene translation and protein production. High concentrations
of ligand added to a binding system produce binding, particu-
larly non-specific binding. When a ligand binds to a receptor of
non-interest is termed as non-specific binding. For example, a
muscarinic receptor antagonist drug can even bind to multiple
type receptors such as histamine receptors. Non-specific bind-
ing is linearly proportional to unbound ligand concentration
and many biological tissues have both saturable and non-
saturable components. Further details pertaining to the non-
specific binding are outlined in Section 3.3. Binding does not
always produce an effect; however, receptors are saturable
binding sites that express an effect.
Receptors are usually activated by dimerization. Ligand
binding to receptor monomers causes them to dimerize by
interactions between the extracellular domains. Dimerization
is likely made by the capacity of membrane proteins to move
laterally within the membrane bilayer (Heldin, 1995). Dimer-
ization triggers the cytoplasmic domains (signalling pathway)
by an autophosphorylation (ability of a species of kinase to
phosphorylate itself) in which the kinase activity of each
monomer phosphorylates the other monomer (Cunningham
et al., 1991).
1.3. Agonist, partial agonist, inverse agonist, biased agonist and
antagonist
Agonist: A drug that mimics the endogenous receptor ligand to
activate the receptor to produce a biological response is called
as an agonist. Several agonists are able to produce the target
maximum response without completely occupying all the
receptors.
Partial agonist: A drug that binds and activates a receptor
but does not elicit a full response is known as a partial agonist.A partial agonist can block the effect of a full agonist. In the
presence of high concentrations of a partial agonist, the action
of a full agonist can be reduced to the maximum response eli-
cited by the partial agonist. However, the intrinsic activity
would be greater than zero but less than 1 that of a full agonist.
Inverse agonist: An inverse agonist is a molecule or agent
that binds to the same receptor site as an agonist and is
considered to be a full agonist. However, it exerts the opposite
pharmacological response to that of a normal agonist, i.e.
demonstrates negative efficacy. Constitutive activity refers to
the ability of a receptor in producing its biological response
in the absence of a bound ligand (Milligan, 2003). The consti-
tutive activity of a receptor may be blocked by an inverse
agonist.
Biased agonist: G protein-coupled receptors (GPCRs) are
capable of signalling with different efficacies to their multiple
downstream pathways, a phenomenon referred to as biased
agonism. Biased agonism is one of the fastest growing areas
in GPCR pharmacology. Biased agonism has been primarily
reported as a phenomenon of synthetic ligands and the biolog-
ical importance of such signalling is unclear (Rajagopal et al.,
2013).
Antagonist: A drug that binds to a receptor but does not eli-
cit a response is referred to as an antagonist. Importantly, the
antagonist must block the action of the agonist at the receptor
site. Antagonist can shift the concentration–response curve of
an agonist to the right by reducing its fractional occupancy.
High concentrations of the antagonist may block the actions
of the agonist completely. However, antagonists have no
intrinsic activity and therefore they do not produce any effects.
There are two main types of antagonists. Competitive antago-
nists compete with the agonist for same receptor binding site,
but the binding is reversible. It shifts the concentration-
response curve of the agonist to the right without any reduc-
tion in maximal response. Non-competitive antagonists bind
irreversibly to a receptor site and thereby reduce the ability
of an agonist to bind and produce a response. The non-
competitive antagonism is a slow process which resulting in
a prolonged antagonistic effect.1.4. Affinity, potency and efficacy
Affinity can be defined as the extent or fraction to which a drug
binds to receptors at any given drug concentration or the
firmness with which the drug binds to the receptor. The
168 M.S. Salahudeen, P.S. Nishtalamathematical model of affinity of a drug for the receptor was
first described by Irving Langmuir Kenakin (2004). Affinity is
one of the factors that determine potency. Affinity is inversely
proportional to the potency of a drug 1
Kd
 
, where Kd is the dis-
sociation constant. The strength of the binding (interaction) of
a ligand and its receptor can be described by affinity. The
higher the Kd value, the weaker the binding and the lower
the affinity. The opposite occurs when a drug has a low Kd.
Potency is a measure of necessary amount of the drug to
produce an effect of a given magnitude. In general, potency
is denoted as the median effective concentration/dose as
EC50/ED50/Kd.
Efficacy (intrinsic activity) is the ability of a drug to illicit a
pharmacological response (physiological) when interaction
occurs with a receptor (relationship between response and
occupancy of receptor). Efficacy depends on the efficiency of
the receptor activation to cellular responses and the formation
of number of drug-receptor complexes.
 Full agonists: efficacy = 1.
 Partial agonists: efficacy > 0 and < 1.
 Competitive antagonists: efficacy = 0.
2. Properties of receptors
The two major properties of receptors are binding and signal
transduction. Binding observes laws of thermodynamics and
is typically stereo-selective, saturable, and reversible in nature.
Signal transduction is the second property of a receptor that
the binding of an agonist must be transduced into some kind
of functional response (biological or physiological). This indi-
cates that two domains exist on a receptor which are ‘a ligand-
binding domain’ and ‘an effector domain’.2.1. Major receptors families
A receptor is any biological macromolecule to which a drug
binds and produces a measurable response. Thus, enzymes
and structural proteins can be considered to be pharmacologic
receptors. However, all plasma proteins are simply binding
sites having no function but responsible for transducing extra-
cellular signals into intracellular responses. Receptors are
mainly divided into four families:
1. Ligand-gated ion channels and voltage-gated sodium
channel.
2. G protein-coupled receptors (GPCRs).
3. Enzyme-linked receptors.
4. Intracellular receptors.
2.1.1. Ligand-gated ion channels (ionophores) and voltage-gated
sodium channel
Ligand-gated ion channels are responsible for regulation of the
flow of ions across cell membranes. The activity of these chan-
nels is regulated by the binding of a ligand to the channel. The
nicotinic acetylcholine receptor (for all anaesthetics) and the
c-aminobutyric acid (GABA) receptor are good examples of
ligand-gated receptors, whose activation permits Cl influxto produce membrane hyperpolarisation and reduced central
transmission.
Voltage-gated sodium channel, is an another important
drug receptor other than ligand-gated ion channels for several
drug classes (e.g. local anaesthetics). The receptor is made
of multiple subunits club together to form an aqueous
pore through which (not only) Na+ ions flow. Binding of
acetylcholine opens the pore allowing Na+ influx to produce
a depolarisation i.e. acetylcholine stimulates the nicotinic
receptor which results in sodium influx, generation of an action
potential, and activation of contraction of skeletal muscle.
2.1.2. G protein-coupled receptors
The GPCRs, also called ‘‘7 Transmembrane (7 TM)” recep-
tors, are integral membrane protein monomers. These recep-
tors comprise a large protein family of transmembrane
receptors. Mainly, three protein families which facilitate the
function of the receptors: the G protein-coupled receptor
kinases (GRKs), the heterotrimeric G proteins, and the b-
arrestins. The primary function is to transduce extracellular
stimuli into intracellular signals. Activation of a GPCR allows
interaction with a G protein, which is composed of a (binds
guanosine triphosphate (GTP)), b and c subunits. These com-
prise muscarinic, adrenergic, and opioid receptors. Activated
Ga subunits then interact with an effector molecule to produce
a second messenger, which then brings about a cellular
response and also interact with ion channels to modulate ion
conductance.
b-arrestins are versatile adapter proteins that form com-
plexes with most of the GPCRs following agonist binding
and phosphorylation of receptors by GRKs (Luttrell and
Lefkowitz, 2002). They act as vital role in the interrelated pro-
cesses of homologous desensitisation and GPCR sequestra-
tion, which lead to the termination of G protein activation.
b-arrestin binding to GPCRs both uncouples receptors from
heterotrimeric G proteins and targets them to clathrin-coated
pits for endocytosis (Luttrell and Lefkowitz, 2002). Originally
discovered GRKs and b-arrestins as molecules desensitise G
protein-mediated signalling. However, the previous research
on the formulation of GRKs and b-arrestins as simply a desen-
sitisation system has proven inadequate to explain many cellu-
lar phenomena. In fact, b-arrestins have emerged as
remarkably versatile adaptor molecules that regulate receptor
endocytosis and also serve as signal transducers in their own
right (DeWire et al., 2007).
2.1.3. Enzyme-linked receptors
These receptors consist of cytosolic enzyme activity as an inte-
gral component of their structure or function. Binding of a
ligand to an extracellular domain activates or inhibits this
cytosolic enzyme activity.
2.1.4. Intracellular receptors
These receptors are entirely intracellular and, therefore, the
ligand must diffuse into the cell to interact with the receptor.3. Ligand binding models
Ligand binding model works on the underpinning PD princi-
ple of a drug eliciting its pharmacological effect at the receptor
Ligand-binding models and applications 169site (Bardal et al., 2010). The pharmacological effect is pro-
duced by the drug binding to the receptor to either mimic or
antagonise the receptor. Largely, the drug concentration at
the site of the receptor determines the intensity of a drug’s
pharmacological effect; however, the drug response could be
influenced by receptor density on the cell surface, signal
transmission mechanism into the cell by second messengers,
or regulatory factors that control gene translation and protein
production (Spruill and Wade, 2010).
Ligand binding models describe a system of interacting
components, i.e. the interaction of one or more ligands with
one or more binding sites. The Emax model is the central
method to describe the concentration/dose-effect relationship.
According to the law of mass action, it has robust theoretical
support from the physicochemical principles governing bind-
ing of drug to a receptor. It predicts a hyperbolic relationship
between the drug concentration and response which is linear.
When dose increases, at certain point the response becomes
saturated and reaches a plateau. All biological responses must
reach a maximum and this is a significant prediction of the
Emax model.
3.1. Theory of receptor binding
In 1926, the drug-receptor binding concept was first intro-
duced by Clark (1926). The occupancy theory of Clark’s was
elaborated by Ariens and De Groot (1954) and Stephenson
(1956) and became a foundation for the field of PDs.
The models used to describe the PD relationship is based on
the receptor binding theory. The assumption made in classical
receptor theory is that a drug binds to a receptor reversibly,
which then provokes a series of biochemical and physiological
changes to produce the observed drug effect. The maximum
drug effect is achieved once all the receptors are occupied.
Binding of drug to receptor is principally the same as drug
to enzyme as defined by the Michaelis–Menten equation
(Berg et al., 2002).
Michaelis–Menten equation:
Bound ¼ Bmax  ½L½L þ Kd
V0 ¼ Vmax  ½S½S þ Km
ð1Þ
where Bmax is the maximum binding capacity, [L] is the ligand
concentration, Kd is the dissociation constant, V0 is the initial
velocity of the reaction, Vmax the maximal rate, ½S is the sub-
strate concentration and Km is Michaelis–Menten constant.
Ligand – receptor binding experiments are usually analysed
according to the simple model of law of mass action.
3.2. Law of mass action
The interaction of drug–receptor complex encompasses chem-
ical bonding, which is normally reversible in nature and can be
expressed using the law of mass action.
In accordance with the law of mass action, a drug (termed as
ligand if it has affinity for a receptor) – receptor interaction is
based on the random coupling of ligand-receptor. The basic
concept is illustrated by the ‘lock and key’ model. The effect that
may be stimulated by this will be proportional to both the
amount of ligand and the amount of receptor. Since, theremay be a finite amount of receptors and concentrations of
ligand may be higher than the affinity constant then the
concentration-response will behave according to a process of
diminishing returns, in the sense that higher concentrations pro-
duce less additional response than would be expected if the rela-
tionship is linear. From the law of mass action, the number of
receptors site ½R occupied by a drug depends on the plasma
drug concentration ½L and the association and dissociation rate
constants (kon and koff) of drug receptor complex.
Ligand – receptor binding experiments are usually analysed
according to the simple model of law of mass action:
Simple binding reaction (reversible):
½L þ ½R ¢kon
koff
½LR ð2Þ
where ½R, ½L; and ½RL represent the free concentration of
receptor, ligand, and receptor-ligand complex, respectively,
and where it is assumed that the reaction components can
freely diffuse within the medium. kon and koff are the rate con-
stants for association and dissociation of the ligand-receptor
complex. It is assumed that after dissociation, receptor and
ligand are not altered.
Usually, the following assumptions are made for this
equation:
 The interaction is reversible.
 The receptor, ligand, and ligand-receptor complex are in
equilibrium.
 The receptor contains one binding site for the ligand.
 The ligand and receptor interact rapidly to form the ligand-
receptor complex.
Association and dissociation rates are temperature depen-
dent. The reaction is driven by the concentration of the react-
ing agents. Equilibrium is reached when the rate at which
ligand-receptor complexes are formed and dissociate are equal.
At equilibrium, the following applies:
½L½Rkon ¼ ½LRkoff3.3. Fractional occupancy
Pharmacologists often use the term fractional occupancy to
describe the fraction of receptors occupied at a particular
ligand concentration Hucho (1993); Ross (1996). The frac-
tional occupancy can be described in another way as shown
in Eq. (3).
Illustration of fractional occupancy:
foccupancy ¼
occupied binding sites
total binding sites
foccupancy ¼
½LR
½total receptors
foccupancy ¼
½LR
½R þ ½LR
ð3Þ
where ½R is the concentration of free receptors and ½LR is the
ligand-receptor complex concentration. In accordance with the
law of mass action a drug (termed as ligand if it has affinity for
a receptor) – receptor interaction is based on the random cou-
pling of ligand-receptor. The equilibrium dissociation constant
170 M.S. Salahudeen, P.S. Nishtala(Kd) represents the inverse of the affinity of the drug for the
receptor and can be defined as;
Equilibrium dissociation constant:
Kd ¼ Koff
Kon
¼ ½L½R½LR ð4Þ
The dissociation constant Kd represents the inverse of the
affinity of the receptor for the ligand when at equilibrium
and if Kd is large then the receptor ligand does not bind readily
but if Kd is small then the receptor binds readily to the ligand.
We know from its definition that Kd is given in Eq. (4).
So if we rearrange to get an equation describing ½LR and
then substitute this in Eq. (3), we get the following:
Fractional occupancy:
foccupancy ¼
½L
½L þ Kd ð5Þ
Pharmacologists are often concerned about the fractional
occupancy because, the effect of a drug should depend on
the fraction of receptors that are actually occupied. Therefore,
the measured effect should depend on the fractional occu-
pancy, which in turn depends on ½Lð½LþKdÞ. Similarly, if we have
measured the maximum effect (where almost 100% of the
receptors are occupied) with known fractional occupancy, then
it is easy to determine the effect for any given concentration of
a ligand. This effect will be given by the following equation:
Derivation of fractional occupancy from Emax model is as
follows:
Effect ¼ Emax  ½L½L þ Kd
From foccupancy ¼
½LR
½R þ ½LR
Multiply by ½L;
foccupancy ¼
½L  ½LR
½L  ½R þ ½L  ½LR
Divide by ½LR
foccupancy ¼
½L  ½LR½LR
½L  ½R½LR þ ½L  ½LR½LR
¼ ½L½L  ½R½LR þ ½L
Substitute in Kd
since; Kd ¼ ½L  ½R½LR ; then
foccupancy ¼
½L
½L þ Kd
ð6Þ
Usually, binding of a ligand to receptors provides a
fractional occupancy measure (f occupancy) based on two
types of binding, (1) specific binding (saturable) and (2) non-
specific binding (non-saturable).
Specific binding relates to receptor occupancy as follows:
Specific binding:
specific binding ¼ foccupancy  Bmax ¼
Bmax  ½L
½L þ Kd
specific binding ¼ total binding nonspecific binding
ð7Þ
where Bmax is the binding maximum which is equivalent to the
maximum number of receptors. Specific binding refers to the
binding of the ligand to the receptor which follows the law
of mass action (mentioned above). The binding curve is iden-tical to the fractional occupancy curve, except it is scaled by
the number of receptors (Bmax). Since there are a finite number
of receptors then the curve reaches an asymptote at the limit of
½L. It is important to note that there may be more than one
population of receptors (more than one Bmax) with more than
one affinity for the drug (recall Kd is the inverse of affinity).
Non-specific binding refers to the binding of a ligand to
components of the experimental matrix other than the receptor.
From a pure pharmacological perspective non-specific binding
is of no importance but from an experimental pharmacological
perspective non-specific binding cannot be avoided. In contrast
to specific binding, non-specific binding is considered to consist
of a virtually unquenchable supply of binding sites – the rela-
tionship is therefore linear. Any experiment that assesses ligand
binding will therefore have to contend with non-specific bind-
ing. It is therefore necessary to be able to assay total binding
of the ligand and non-specific binding, then specific binding
(what we are interested in) is calculated as the difference.
Interaction of a drug with a receptor can be described by
two parameters. Affinity describes strength of drug binding
with receptor (‘‘fit the lock”). Efficacy describes ability of
drug-bound receptor to produce a response (‘‘turn the key”).
Agonists have both affinities for the receptor as well as efficacy
but antagonists have only affinity for the receptors and no
(zero) efficacy.
3.4. Applications of ligand binding model (Pollard, 2010)
Ligand binding models have broad applications in clinical
pharmacology;
 Ligand binding models can explain a system of interacting
elements of multiple ligands with multiple binding receptor
sites.
 The time course of binding (association and dissociation)
can be described using ligand binding models however, it
is more common to describe binding at the equilibrium.
 Receptor binding properties for disease states can be
assessed using the experimental setup with neurotransmit-
ters (e.g. acetylcholine), and radioimmunoassay’s.
 Ligand binding models are useful in the drug development
process to identify the binding sites of receptors.
 Ligand binding models are useful to demonstrate multiple
binding sites and receptors simultaneously.
 Ligand binding models are also very useful to compare the
affinities of different ligands for a same receptor. The
Cheng and Prusoff equation (Cheng and Prusoff, 1973)
allows to calculate the Ki (inhibition constant) from the
inhibition concentration (IC50).4. Pharmacodynamic (dose-response) models
PD models generally examine the plasma concentration and
effect relationship. It can predict the archetypal effect (E) of
a drug as a function of the drug concentration (C) and an
unknown PD parameter (hpd) can be estimated. The PD
models have been described as fixed, linear, log-linear, Emax,
sigmoid Emax, and indirect PD response.
The mathematical form of a PD model:
EðCÞ ¼ fðC; hpdÞ ð8Þ
Figure 2 The drug concentration-response (pharmacodynamic) relationship.
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It is defined as the relationship between an endogenous and
exogenous ligand that binds to a receptor to produce a desired
pharmacological effect. This effect can be a maximum (Emax) in
which further increase in the concentration does not result in
higher response called saturation point.
Fig. 2 describes the linear and semi-log approaches to
concentration-response relationship. When plotted on a linear
scale (left panel), a concentration-response relationship is
hyperbolic, and can typically be well described by a Langmuir
binding isotherm. The response reaches maximum at high con-
centrations due to saturation of available receptors by drug.
When plotted on a semi-log scale (logarithm of drug concen-
tration vs. effect), the relationship becomes sigmoidal (S-
shaped). The semi-log plot is the preferred method for plotting
concentration-response relationships because it becomes easier
to accurately determine the EC50 value (the concentration
which produces 50% of the maximum response) by placing it
on a linear portion of the curve (semi-log plot). Higher the
EC50, lower the potency.
4.2. Emax model
This is a nonlinear mathematical model that is derived from
the classic drug receptor theory. The Emax model is the central
method to describe the concentration-effect relationship.
According to the law of mass action, it has strong theoretical
support from the physicochemical principles governing bind-
ing of drug to a receptor. It predicts a hyperbolic relationship
between the drug concentration and response which is linear.
When dose increases, at certain point the response become sat-
urated and reaches a plateau. All biological responses must
reach a maximum and this is a significant prediction of the
Emax model. A recent study has shown the application of using
similar expanded model to examine patient characteristics that
predict adverse anticholinergic-type events in older people
(Salahudeen et al., 2015).
The Emax model:
E ¼ Emax  C
EC50 þ Cor
E ¼ Emax D
ED50 þD ð9Þ
where Emax is the maximal effect of a drug, C is the drug
concentration or D is the drug dose, and EC50 is the drug
concentration resulting in half maximal effect or ED50 is the
dose that produce 50% of the maximal effect.
It can be seen from the above equation that EC50=ED50 can
be directly linked to the kinetics of the drug with the receptor
Kd. Emax model can be further improved by incorporating E0
(baseline estimate in the absence of a drug) which account
for the baseline physiological conditions such as blood pres-
sure baseline.
The Emax model with the baseline of the system E0:
E ¼ E0 þ Emax  C
EC50 þ C
or
E ¼ E0 þ Emax D
ED50 þD
ð10Þ4.3. Sigmoid Emax model
In addition, many drugs seem to have a steeper relationship of
concentration and effect so that a smaller change is required.
These steeper relationships can be described by the sigmoidal
Emax model (Eq. (11)) (Goutelle et al., 2008). This model is
an extension of Emax model that takes into account for multiple
drug binding sites at the same receptor which introduces the
Hill coefficient c to define s-shaped asymptotic behaviour in
the model. In fact, ‘Hill coefficient’ should be referred to as c
if it is an integer that is mechanistically derived based on the
theory of allosteric binding of multiple ligands to the same
receptor site (Hill, 1910). But, in a modelling perspective it
can be estimated as an empirical exponent that is allowed to
take any positive value.
The sigmoidal Emax model is as follows:
E ¼ E0 þ Emax  C
c
ECc50 þ Cc
ð11Þ
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physiologist named Hill to explain the association of oxygen
with haemoglobin (Hill, 1910). He noted that it was steeper
than the simple binding predictions of the Emax model when
he adds an exponential parameter to the effective concentra-
tion, EC50. This equation has been further applied to PDs by
Wagner (1968). Mathematically, this equation is an extension
of the Emax model by adding the Hill coefficient (c). Hill
coefficient determines ‘steepness’ of the effect versus concen-
tration curve to be steeper (if values of c is greater than one)
or shallower (if values of c is lower than one). Fig. 3 shows
the sigmoid Emax model with different values for the Hill coef-
ficient and the consequent effect on the shape of the fractional
effect vs. concentration curve.
4.4. Competitive binding model
The interaction between two and three ligands (drugs) at the
same receptor binding site can usually be described by a com-
petitive ligand binding model. The term ‘competition’ in this
scenario usually denotes the antagonism in which two ligands
are proficient of binding to the same receptor site. The compet-
itive binding models use a labelled concentration of ligand in
the presence of various unlabelled ligand concentrations
(known as the competitor or inhibitor) and measure binding
at equilibrium. The concentration of displacing ligand increase
is equivalent to change in the apparent value of the dissocia-
tion constant (Kd). Competition binding models are useful
for determining whether the unlabelled ligand has affected
the ligand’s affinity for the receptor and compare the affinities
of several ligands for the same receptor to find total versus free
concentration or dose for the labelled ligand and unlabelled
competitor or inhibitor.
Competitive binding model for two-ligand and one binding
site is as follows:
E ¼ Emax  ½LR½Rtotal
 
¼ Emax  ½L1½R½R þ ½L1½R þ ½L2½R
 
E ¼ Emax 
½L1 ½R
Kd1
½R þ ½L1 ½R
Kd1
þ ½L2 ½R
Kd2
 !Figure 3 The sigmoid Emax model with different values for the
hill coefficient.E ¼ Emax 
½L1
Kd1
1þ ½L1
Kd1
þ ½L2
Kd2
 !
E ¼ Emax  ½L1
½L1 þ Kd1 1þ ½L2Kd2
 
0
@
1
A ð12Þ
where the dissociation constants Kd1 and Kd2 represent the
first and second ligands ½L1 and ½L2.
Competitive binding model for three-ligand and one bind-
ing site is as follows:
E ¼ Emax  ½L1
½L1 þ Kd1 1þ ½L2Kd2 þ
½L3
Kd3
h i
0
@
1
A ð13Þ
whereas the dissociation constants Kd1, Kd2 and Kd3 represent
the first, second and third ligands.
The aforementioned Eq. (12) will change eventually with
the following conditions in terms of fractional occupancy:
If the same drug has given twice:
Same drug given twice:
foccupancy ¼
ðL1 þ L2Þ
Kdþ ðL1 þ L2Þ ð14Þ
Similar potency of drugs occurs when, ED50ð1Þ ¼ ED50ð2Þ
Drugs with same potency:
foccupancy ¼
ðL1 þ L2Þ
Kdþ ðL1 þ L2Þ ð15Þ
Different potency occurs when, ED50ð1Þ–ED50ð2Þ
In this model, the equation is rewritten as;
Drugs with different potency:
foccupancy ¼
L1
Kd1
þ L2
Kd2
L1
Kd1
þ 1þ L2
Kd2
  ð16Þ
The above equation is normalised for L1 and L2 and works
even in the absence of any one drug. If we consider, L1
Kd1
as ‘a’
and L2
Kd2
as ‘b’, the above equation would change to:
Simplified version of Eq. (16):
foccupancy ¼
aþ b
ð1þ bÞ þ a ð17Þ
Competitive binding model for more than one ligands and two
binding sites is depicted below;
Competitive binding model for two-ligand and two binding
sites:
E ¼ Emaxð1Þ  ½L1
½L1 þ Kd1ð1Þ 1þ ½L2Kd2ð1Þ
 þ Emaxð2Þ  ½L1
½L1 þ Kd1ð2Þ 1þ ½L2Kd2ð2Þ
 
0
@
1
A
ð18Þ
where the dissociation constants Kd1ð1Þ; Kd1ð2Þ and
Kd2ð1Þ; Kd2ð2Þ for the first and second ligands ½L1 and ½L2 with
respect to the two receptor binding sites having Emaxð1Þ and
Emaxð2Þ.
Competitive binding models become more complex when
the number of receptor binding sites and number of ligands
increases.
Ligand-binding models and applications 1734.5. Applications of Emax model
 Emax model possess a widespread application in the field of
functional receptor pharmacology.
 Re-arrangement of Emax equation can lead to a prediction
of target concentration or dose to reach the target effect,
C ¼ EC50EEmaxE.
 A useful model and a common descriptor for characterising
dose-response relationship.
 Dose-response of drug is monotonic and can be modelled as
continuous and also can account for a range of different
dose levels.
 Emax model can be a useful tool in determining the ‘optimal’
dose and the ‘minimal effective dose’.
 Emax model-based drug development and therapeutics is
promising and can explain the mechanism-based PD
modelling.
 Emax model can predict a zero-dose baseline effect (E0) in
the absence of no drug and also follows the ‘law of dimin-
ishing returns’ at higher doses.
 It is straight-forward to implement in any modelling soft-
ware (for example; NONMEM, S-plus, SAS Proc NLIN).
A recent study employed an Emax model to examine patient
characteristics that predict adverse anticholinergic-type events
in older people (Salahudeen et al., 2015). The authors explored
the influence of patient characteristics using a nonlinear model
(Emax), to test whether they (1) increased the risk of adverse
events independent of anticholinergic burden (i.e. they pose a
risk even in the absence of anticholinergic burden) by adding
patient characteristics to the baseline (b0), (2) increased the risk
of adverse effects in the presence of anticholinergic burden (i.e.
an overall greater effect is seen with anticholinergic burden) by
including interaction of patient characteristics with Emax or (3)
increased the apparent potency of the anticholinergic burden
(i.e. greater effects were seen for a given anticholinergic burden
value) by adding a patient characteristics to ED50 that provides
50% of the maximal effect.5. Population analysis
For predicting a drug response in a given population, a model
must be designed that it best describes the relationship between
dose, time and effect and also accounts for the variability (e.g.
inter/intra-individual) of dose-response among all individuals
in the population. However, it is known that data collected
from the clinical studies may have huge variability and uncer-
tainty. There are three main population analysis approaches:
the two stage approach, Naı¨ve pooled data approach, and a
full population based approach.
The two-stage approach is relatively a simple method to esti-
mate the between subject variability (BSV) in addition to the
population mean parameters and the data for each individual
are analysed separately. In this approach, it requires rich data
for each individual and the obtained BSV tends to be inflated
compared to the true variability. Naı¨ve pooled approach anal-
yses data as if it has arisen from just a single individual and the
whole dataset is pooled together to estimate just one set of
parameter values for the model. With regard to computational
effort, this method is the least complex approach and does notaccount for the BSV. A full population based approach delivers
an accurate and precise way of quantification of the population
mean parameter estimates including residual unexplained vari-
ance (RUV) and BSV for a given dataset. Besides, this
approach is able to handle sparse data. The dose-response rela-
tionship can be best described using a population model (full
population approach) that correlates each individual in that
given population. The mean model parameters (RUV and
BSV) are also estimated from the population analysis.
5.1. Nonlinear mixed effects modelling
Nonlinear Mixed Effects Modelling (NLME) also called hier-
archical nonlinear models is useful for estimating population
parameters and variance, accounting for both random and
fixed effects Davidian and Giltinan (1995). NLME modelling
approach is used routinely to model sparse data particularly
relevant to pre-clinical or clinical trials where complete patient
data may not be available. The NLME models for fixed effects,
where variables in the sample (or population) do not change
over time, and for random effects where variables are time-
dependent. A full population based approach is desired for
precise quantification of the population mean parameter esti-
mates including RUV and BSV. However, the NLME is a rea-
sonable approach for parameter estimation with sparse data
and data on some variables are incomplete. NMLE can anal-
yse and quantify data pertaining to a series of individuals with
differences in drug response, examining multiple covariates
(such as age, sex, ethnicity, comorbidity index, weight, and
organ function) that explain the variability between individuals
to some extent and also help in dose-individualisation.
Several software programs are available for nonlinear
mixed effects modelling, but among these the widely used
one is NONMEM (Nonlinear Mixed Effects Modelling)
(ICON Development Solutions, Ellicott City, MD), which is
a computer program, written using Abbreviated Fortran,
designed to fit general statistical (nonlinear) regression models
to data for the analysis of population pharmacokinetic and PD
information (Beal et al., 2009). NONMEM uses maximum
likelihood approach to estimate the population parameters
such as mean, RUV, and BSV.
Maximum likelihood estimation (MLE) approach consid-
ers that the parameters in the model are fixed but with
unknown quantities (values) by maximising the probability
of obtaining the observed data. The MLE is an indispensable
approach in non-linear modelling assuming the distribution
of data is not normal. MLE is employed routinely in inferen-
tial statistics, and in well-known model selection criteria such
as Akaike information criteria (AIC) and Bayesian informa-
tion criteria (BIC) use MLE. NONMEM allows for ‘mixed
effects modelling’ by accounting for both unexplainable
inter-individual and intra-individual effects (random effects),
as well as measured concomitant effects (fixed effects) for
proper modelling of such data.6. Concluding remarks and future direction
Receptor binding has revolutionised the field of drug discovery
(Leysen et al., 2010). Drug-receptor binding profiles of certain
central nervous system (CNS) drugs such as antipsychotics and
antidepressants have revealed that they bind to multiple
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chotic clozapine binds to more than twenty receptors and all of
them could result in therapeutic response) (Leysen, 2002,
2004). Application of the binding model may help understand
relative effect of these responses. Current research on central
nervous system focuses on ex vivo autoradiography using mea-
sured fractional receptor occupancy in the brain by the drugs
that are administered to animals. It allows to identify the
dose-range of a drug at which the central receptors are occu-
pied and are beneficial to determine the delivery of drugs into
the CNS (Leysen et al., 2010).
Ligand binding model can incorporate multiple drugs affin-
ity to the receptor till the receptor occupancy is saturated and
exhibits maximum threshold effect. Once after saturation of
these receptors, there will be no further pharmacological
response. Also, the model would be helpful in predicting the
relative effect of single or multiple medicines.
For ligand binding models, the term fractional occupancy
used to best describe the fraction of receptors occupied at
a particular ligand concentration. It is stated that the
fractional occupancy¼ occupied binding sites=total binding sites,
which means that the effect of a drug should depends on the
fraction of receptors that are actually occupied. So, the mea-
sured effect would depend on the fractional occupancy. If
the measured effect is maximum (where almost 100% of the
receptors are occupied) and a known fractional occupancy,
the effect for any given concentration of a ligand could be
determined.
In the future, network-based systems pharmacology models
could be an effective way of understanding drug-related
adverse effects (Berger and Iyengar, 2011). The advantages of
network-based systems pharmacology models comprise the fol-
lowing: increase in drug efficacy, regulation of the signalling
pathway with multiple channels, increase in drug efficacy,
increase in the success rate of clinical trials, and decrease in
the costs of drug discovery (Wu et al., 2013). Network pharma-
cology models make two main approaches in the drug develop-
ment process. One is to establish a pragmatic network model
and predict the drug target based on public databases or avail-
able data of earlier researches. The second approach is to
reconstruct a ‘‘drug target disease” network prediction model
using the high-throughput screen technology and bioinformatic
methods. In this approach, the mechanism of drugs in the bio-
logical network could be analysed by comparing the interaction
between the drug and the model. The emphasis on mechanistic
models may open new opportunities for clinical researchers to
rationalise drug therapy in clinical practice.Funding
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